{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:02:21Z","timestamp":1792555341819,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tubulointerstitial nephritis with IgM-positive plasma cells (IgMPC-TIN) is a newer disease about which there are many unclear points. Glucocorticoid therapy is effective in many cases of IgMPC-TIN; however, relapse during glucocorticoid tapering has been reported. Relapse and its treatment are poorly defined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case Presentation<\/jats:title>\n                <jats:p>Case 1 was a 61-year-old man with renal dysfunction and proteinuria. Tubulointerstitial nephritis and IgM-positive plasma cells were observed in a renal biopsy. He was diagnosed with IgMPC-TIN accompanied by Fanconi syndrome and distal renal tubular acidosis (d-RTA). Prednisolone (PSL; 30\u00a0mg daily, 0.45\u00a0mg\/kg\/day) treatment was highly effective, and PSL was gradually tapered and discontinued after 1\u00a0year. However, 1\u00a0month after PSL discontinuation, therapeutic markers were elevated. Therefore, PSL (10\u00a0mg daily, 0.15\u00a0mg\/kg\/day) was administered, and the markers indicated improvement.<\/jats:p>\n                <jats:p>Case 2 was a 43-year-old woman referred for renal dysfunction and proteinuria. Laboratory data revealed that she had primary biliary cholangitis (PBC), d-RTA, and Fanconi syndrome. A renal biopsy showed accumulation of IgM-positive plasma cells in the tubulointerstitium without any glomerular changes. A diagnosis of IgMPC-TIN was made and the patient was started on PSL (35\u00a0mg daily, 0.6\u00a0mg\/kg\/day). Therapeutic markers decreased immediately and PSL was discontinued after 1\u00a0year. Three months later, the proteinuria and Fanconi syndrome worsened. PSL treatment was restarted (20\u00a0mg daily, 0.35\u00a0mg\/kg\/day) and markers indicated improvement.<\/jats:p>\n                <jats:p>Case 3 was a 45-year-old woman with renal dysfunction and proteinuria. Tubulointerstitial nephritis and IgM-positive plasma cells were observed in a renal biopsy. The patient had PBC, Sj\u00f6gren syndrome, d-RTA, and Fanconi syndrome, and the diagnosis of IgMPC-TIN was made. The patient was started on PSL (30\u00a0mg daily, 0.4\u00a0mg\/kg\/day) and disease markers decreased immediately. However, when PSL was tapered to 15\u00a0mg daily (0.2\u00a0mg\/kg\/day), the patient\u2019s serum IgM levels increased; therefore, we maintained the PSL at 15\u00a0mg daily (0.2\u00a0mg\/kg\/day).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We report three cases of relapsed IgMPC-TIN associated with reduction or discontinuation of glucocorticoid therapy. In these cases, elevation of serum IgM preceded that of other markers such as urinary \u03b2<jats:sub>2<\/jats:sub>-microglobulin, proteinuria, and glycosuria. We recommend monitoring serum IgM levels while tapering glucocorticoids; a maintenance dose of glucocorticoid should be considered if relapse is suspected or anticipated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03253-8","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T04:02:09Z","timestamp":1688443329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A report of three cases of patients with tubulointerstitial nephritis with IgM-positive plasma cells, treatment, and serum-IgM as a sensitive marker for relapse"],"prefix":"10.1186","volume":"24","author":[{"given":"Ryota","family":"Akagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Minamiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"issue":"10","key":"3253_CR1","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/ki.2010.271","volume":"78","author":"T Saeki","year":"2010","unstructured":"Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78(10):1016\u201323.","journal-title":"Kidney Int"},{"issue":"12","key":"3253_CR2","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1681\/ASN.2016101074","volume":"28","author":"N Takahashi","year":"2017","unstructured":"Takahashi N, Saeki T, Komatsuda A, et al. Tubulointerstitial nephritis with IgM-positive plasma cells. J Am Soc Nephrol. 2017;28(12):3688\u201398.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"3253_CR3","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1097\/01.ASN.0000023430.92674.E5","volume":"13","author":"SJ Rodr\u00edguez","year":"2002","unstructured":"Rodr\u00edguez SJ. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13(8):2160\u201370.","journal-title":"J Am Soc Nephrol"},{"issue":"9377","key":"3253_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(03)13808-1","volume":"362","author":"JA Talwalkar","year":"2003","unstructured":"Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362(9377):53\u201361.","journal-title":"Lancet"},{"issue":"6","key":"3253_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3109\/s10165-004-0338-x","volume":"14","author":"T Fujibayashi","year":"2004","unstructured":"Fujibayashi T, Sugai S, Miyasaka N, et al. Revised Japanese criteria for Sj\u00f6gren\u2019s syndrome (1999): availability and validity. Mod Rheumatol. 2004;14(6):425\u201334.","journal-title":"Mod Rheumatol"},{"issue":"9","key":"3253_CR6","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.ekir.2020.06.010","volume":"5","author":"N Matsuoka-Uchiyama","year":"2020","unstructured":"Matsuoka-Uchiyama N, Tsuji K, Fukushima K, et al. Tubulointerstitial nephritis cases with IgM-positive plasma cells. Kidney Int Rep. 2020;5(9):1576\u201380.","journal-title":"Kidney Int Rep"},{"issue":"19","key":"3253_CR7","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2169\/internalmedicine.7118-21","volume":"60","author":"M Minato","year":"2021","unstructured":"Minato M, Murakami T, Takahashi N, et al. Glucocorticoid-dependent tubulointerstitial nephritis with IgM-positive plasma cells presenting with intracellular crystalline inclusions within the rough endoplasmic reticulum. Intern Med. 2021;60(19):3129\u201336.","journal-title":"Intern Med"},{"issue":"4","key":"3253_CR8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ekir.2018.04.001","volume":"3","author":"S Mizoguchi","year":"2018","unstructured":"Mizoguchi S, Katayama K, Murata T, et al. IgM-positive tubulointerstitial nephritis associated with asymptomatic primary biliary cirrhosis. Kidney Int Rep. 2018;3(4):1004\u20139.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3253_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12882-015-0184-4","volume":"16","author":"S Yamaguchi","year":"2015","unstructured":"Yamaguchi S, Maruyama T, Wakino S, et al. A case of severe osteomalacia caused by Tubulointerstitial nephritis with Fanconi syndrome in asymptomotic primary biliary cirrhosis. BMC Nephrol. 2015;16(1):187.","journal-title":"BMC Nephrol"},{"issue":"11","key":"3253_CR10","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1093\/ndt\/gfq232","volume":"25","author":"A Komatsuda","year":"2010","unstructured":"Komatsuda A, Wakui H, Ohtani H, et al. Tubulointerstitial nephritis and renal tubular acidosis of different types are rare but important complications of primary biliary cirrhosis. Nephrol Dial Transplant. 2010;25(11):3575\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3253_CR11","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1053\/j.ajkd.2005.05.021","volume":"46","author":"M Lino","year":"2005","unstructured":"Lino M, Binaut R, Noel LH, et al. Tubulointerstitial nephritis and Fanconi syndrome in primary biliary cirrhosis. Am J Kidney Dis. 2005;46(3):e41\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3253_CR12","first-page":"467","volume":"26","author":"B Terrier","year":"2008","unstructured":"Terrier B, Fakhouri F, Berezne A, et al. Osteomalacia revealing celiac disease and primary biliary cirrhosis-related Fanconi syndrome in a patient with systemic sclerosis. Clin Exp Rheumatol. 2008;26(3):467\u201370.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"3253_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ckj\/sfs085","volume":"5","author":"T Bansal","year":"2012","unstructured":"Bansal T, Takou A, Khwaja A. Progressive chronic kidney disease secondary to tubulointerstitial nephritis in primary biliary cirrhosis. Clin Kidney J. 2012;5(5):442\u20134.","journal-title":"Clin Kidney J"},{"issue":"4","key":"3253_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2169\/internalmedicine.52.9003","volume":"52","author":"T Iwakura","year":"2013","unstructured":"Iwakura T, Fujigaki Y, Matsuyama T, et al. Tubulointerstitial nephritis and primary biliary cirrhosis with a T cell-dominant profile of infiltrating cells and granulomas in both organs. Intern Med. 2013;52(4):467\u201371.","journal-title":"Intern Med"},{"issue":"2","key":"3253_CR15","first-page":"29","volume":"3","author":"MH Rasolzadegan","year":"2014","unstructured":"Rasolzadegan MH, Bakhshayesh H, Amid N. Tubulointerstitial nephritis associated with primary biliary cirrhosis. J Nephropharmacol. 2014;3(2):29\u201331.","journal-title":"J Nephropharmacol"},{"issue":"14","key":"3253_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(14):457\u201365.","journal-title":"Expert Opin Drug Saf"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03253-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03253-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T04:05:55Z","timestamp":1688443555000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03253-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03253-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"26 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was written in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consent was obtained from the three patients for publication of this case series.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}